Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 176 articles:
HTML format



Single Articles


    November 2022
  1. CWYNARSKI K, Cummin T, Osborne W, Lewis J, et al
    Management of secondary central nervous system lymphoma.
    Br J Haematol. 2022 Nov 21. doi: 10.1111/bjh.18539.
    PubMed    


  2. SHAH H, Jang H, Kim S, Halwani AS, et al
    A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race.
    Br J Haematol. 2022 Nov 18. doi: 10.1111/bjh.18564.
    PubMed     Abstract available


  3. DONG Q, Wang Y, Xiu Y, Sakr H, et al
    Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
    Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.
    PubMed    


  4. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    PubMed     Abstract available


    October 2022
  5. SAIZ LC, Leache L, Gutierrez-Valencia M, Erviti J, et al
    Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?
    Br J Haematol. 2022 Oct 25. doi: 10.1111/bjh.18505.
    PubMed    


  6. SHARGIAN L, Raanani P, Yeshurun M, Gafter-Gvili A, et al
    CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2022 Oct 25. doi: 10.1111/bjh.18506.
    PubMed    


  7. MUNTANOLA A, Mozas P, Mercadal S, Huguet M, et al
    Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Br J Haematol. 2022 Oct 19. doi: 10.1111/bjh.18522.
    PubMed     Abstract available


  8. KNORR F, Woessmann W
    Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma-Response.
    Br J Haematol. 2022 Oct 19. doi: 10.1111/bjh.18528.
    PubMed    


  9. HESS G, Dreyling M, Oberic L, Gine E, et al
    Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
    Br J Haematol. 2022 Oct 18. doi: 10.1111/bjh.18519.
    PubMed     Abstract available


  10. BERTINCHAMP R, Garzaro M, Boutboul D, Galicier L, et al
    Mantle cell lymphoma in human immunodeficiency virus-infected patients.
    Br J Haematol. 2022 Oct 12. doi: 10.1111/bjh.18493.
    PubMed    


  11. CHEN M, Ouyang F, Wu T, Hu Y, et al
    Remission of extranodal NK/T-cell lymphoma, nasal type, after SARS-CoV-2 vaccination.
    Br J Haematol. 2022 Oct 5. doi: 10.1111/bjh.18496.
    PubMed    


  12. AGARWAL G, Moule S, Cope A, Maudgil D, et al
    Spontaneous splenic rupture as initial presentation of diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Oct 3. doi: 10.1111/bjh.18471.
    PubMed    


  13. SMITH OP
    Denis Burkitt: A cancer, the virus and the prevention of man-made diseases.
    Br J Haematol. 2022;199:297.
    PubMed    


    September 2022
  14. ZIJTREGTOP EAM, Diez C, Zwaan CM, Veening MA, et al
    Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
    Br J Haematol. 2022 Sep 20. doi: 10.1111/bjh.18473.
    PubMed     Abstract available


  15. GISSELBRECHT C, Sibon D
    Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
    Br J Haematol. 2022 Sep 19. doi: 10.1111/bjh.18468.
    PubMed     Abstract available


  16. FURQAN F, Ahn KW, Chen Y, Kaur M, et al
    Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
    Br J Haematol. 2022 Sep 19. doi: 10.1111/bjh.18467.
    PubMed     Abstract available


  17. CHERNG HJ, Xu G, Feng L, Steiner R, et al
    Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
    Br J Haematol. 2022 Sep 6. doi: 10.1111/bjh.18441.
    PubMed     Abstract available


  18. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    PubMed     Abstract available


  19. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    PubMed     Abstract available


  20. DHOLARIA B, Mehraban N, Baer B, Long N, et al
    Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
    Br J Haematol. 2022;198:1073-1075.
    PubMed    


    August 2022
  21. NAKHODA S, Vistarop A, Wang YL
    Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
    PubMed     Abstract available


  22. LIM SH
    COVID-19 infection in primary central nervous system lymphoma treatment: Who is most at risk?
    Br J Haematol. 2022 Aug 26. doi: 10.1111/bjh.18416.
    PubMed    


  23. RAJAMAKI A, Hujo M, Sund R, Prusila REI, et al
    Link between disease status at 24 months and mortality in follicular lymphoma.
    Br J Haematol. 2022 Aug 26. doi: 10.1111/bjh.18423.
    PubMed    


  24. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    PubMed     Abstract available


  25. BINKLEY MS
    Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 22. doi: 10.1111/bjh.18406.
    PubMed     Abstract available


  26. NAIK A, Gooley T, Loeb K, Soma L, et al
    The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment.
    Br J Haematol. 2022 Aug 16. doi: 10.1111/bjh.18404.
    PubMed     Abstract available


  27. JESSA R, Chien N, Villa D, Freeman CL, et al
    Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
    Br J Haematol. 2022 Aug 12. doi: 10.1111/bjh.18399.
    PubMed     Abstract available


  28. STEFFANONI S, Calimeri T, Laurenge A, Fox CP, et al
    Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
    Br J Haematol. 2022 Aug 9. doi: 10.1111/bjh.18396.
    PubMed     Abstract available


  29. TARANTELLI C, Bertoni F
    United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Aug 2. doi: 10.1111/bjh.18384.
    PubMed     Abstract available


  30. ROSLER W, Zenz T
    GOALs in relapsed DLBCL.
    Br J Haematol. 2022;198:419-420.
    PubMed    


    July 2022
  31. O'REILLY MA, Sanderson R, Wilson W, Iyengar S, et al
    Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapse
    Br J Haematol. 2022 Jul 27. doi: 10.1111/bjh.18378.
    PubMed    


  32. WEINSTOCK M, Elavalakanar P, Bright S, Ambati SR, et al
    Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Br J Haematol. 2022 Jul 27. doi: 10.1111/bjh.18383.
    PubMed     Abstract available


  33. HARTMANN S, Soltani AS, Bankov K, Bein J, et al
    Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2022 Jul 26. doi: 10.1111/bjh.18376.
    PubMed     Abstract available


  34. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    PubMed     Abstract available


  35. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.
    PubMed    


  36. DU W, Estalilla OC, Jelic TM, Hayes JD, et al
    Bone marrow involvement by breast implant-associated anaplastic large cell lymphoma.
    Br J Haematol. 2022 Jul 14. doi: 10.1111/bjh.18364.
    PubMed    


  37. PICARDI M, Giordano C, Pugliese N, Esposito M, et al
    Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.
    Br J Haematol. 2022 Jul 12. doi: 10.1111/bjh.18348.
    PubMed     Abstract available


    June 2022
  38. SHARGIAN L, Raanani P, Yeshurun M, Gafter-Gvili A, et al
    Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2022 Jun 28. doi: 10.1111/bjh.18335.
    PubMed     Abstract available


  39. KAWASAKI N, Nishito Y, Yoshimura Y, Yoshiura S, et al
    The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Jun 28. doi: 10.1111/bjh.18341.
    PubMed     Abstract available


  40. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
    PubMed    


  41. MIAN A, Bhattarai N, Sheu M, Ondrejka SL, et al
    Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.
    Br J Haematol. 2022 Jun 22. doi: 10.1111/bjh.18333.
    PubMed    


  42. KAJI FA, Martinez-Calle N, Sovani V, Fox CP, et al
    Rare central nervous system lymphomas.
    Br J Haematol. 2022;197:662-678.
    PubMed     Abstract available


    May 2022
  43. STRUSSMANN T, Glatzki F, Engelhardt M, Mertelsmann R, et al
    Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.
    Br J Haematol. 2022 May 27. doi: 10.1111/bjh.18280.
    PubMed    


  44. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    PubMed     Abstract available


  45. DAWUDI Y, Benali K, Beydon M, Hourseau M, et al
    B-cell lymphoma mimicking relapsing polychondritis.
    Br J Haematol. 2022 May 20. doi: 10.1111/bjh.18220.
    PubMed    


  46. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed     Abstract available


  47. ARMITAGE JO, Gale RP, Jaffe ES
    Lymphoma Nomenclature - What's in a name?
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18063.
    PubMed    


  48. MOMOTOW J, Buhnen I, Trautmann-Grill K, Kobbe G, et al
    Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18231.
    PubMed    


  49. DITTUS C, Miller JA, Wehbie R, Castillo JJ, et al
    Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
    Br J Haematol. 2022 May 4. doi: 10.1111/bjh.18228.
    PubMed    


  50. DIXON JG, Dimier N, Nielsen T, Zheng J, et al
    End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18217.
    PubMed     Abstract available


  51. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available


    April 2022
  52. KUHNL A, Roddie C, Kirkwood AA, Tholouli E, et al
    A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
    Br J Haematol. 2022 Apr 29. doi: 10.1111/bjh.18209.
    PubMed     Abstract available


  53. CALABRETTA E, Guidetti A, Ricci F, Di Trani M, et al
    Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18183.
    PubMed     Abstract available


  54. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
    Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18197.
    PubMed     Abstract available


  55. TANIGUCHI T, Nakayama S, Tanaka H, Rai S, et al
    Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.
    Br J Haematol. 2022 Apr 22. doi: 10.1111/bjh.18208.
    PubMed     Abstract available


  56. MANSON G, Herbaux C, Schiano JM, Casasnovas O, et al
    Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
    Br J Haematol. 2022 Apr 21. doi: 10.1111/bjh.18198.
    PubMed    


  57. EL-GALALY TC, Glimelius I
    Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
    Br J Haematol. 2022 Apr 19. doi: 10.1111/bjh.18199.
    PubMed     Abstract available


  58. ETHIRAJ P, Sasi B, Holder KN, Lin AP, et al
    Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1alpha intersect to regulate angiogenesis in B-cell lymphoma.
    Br J Haematol. 2022 Apr 12. doi: 10.1111/bjh.18196.
    PubMed     Abstract available


  59. ANDERSEN MD, Hamilton-Dutoit S, Modvig L, Vase M, et al
    Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
    Br J Haematol. 2022 Apr 8. doi: 10.1111/bjh.18180.
    PubMed     Abstract available


  60. EKELS A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, et al
    Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.
    Br J Haematol. 2022 Apr 2. doi: 10.1111/bjh.18139.
    PubMed     Abstract available


  61. SHANKAR A, Hall GW, McKay P, Gallop-Evans E, et al
    Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18169.
    PubMed     Abstract available


  62. HESS G, Huttmann A, Witzens-Harig M, Dreyling MH, et al
    A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18161.
    PubMed     Abstract available


  63. PASZKIEWICZ-KOZIK E, Michalski W, Taszner M, Mordak-Domagala M, et al
    Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18166.
    PubMed     Abstract available


  64. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available


  65. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available


    March 2022
  66. TERAS LR, Bertrand KA, Deubler EL, Chao CR, et al
    Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States.
    Br J Haematol. 2022 Mar 29. doi: 10.1111/bjh.18150.
    PubMed     Abstract available


  67. MERCADAL S, Alana M, Barcelo MI, Bruixola G, et al
    Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain.
    Br J Haematol. 2022 Mar 20. doi: 10.1111/bjh.18148.
    PubMed    


  68. GHOLIHA AR, Hollander P, Lof L, Glimelius I, et al
    Checkpoint CD47 expression in classical Hodgkin lymphoma.
    Br J Haematol. 2022 Mar 17. doi: 10.1111/bjh.18137.
    PubMed     Abstract available


  69. BROCKELMANN PJ, Borchmann P
    Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.
    Br J Haematol. 2022 Mar 9. doi: 10.1111/bjh.18130.
    PubMed    


  70. RIISE J, Meyer S, Blaas I, Chopra A, et al
    Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination.
    Br J Haematol. 2022 Mar 7. doi: 10.1111/bjh.18149.
    PubMed     Abstract available


  71. EYRE TA, Jensen P, Booth S, El-Galaly TC, et al
    Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.
    Br J Haematol. 2022 Mar 2. doi: 10.1111/bjh.18104.
    PubMed     Abstract available


  72. PALLETT SJC, Wake R, Youngs J, Pope C, et al
    Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.
    Br J Haematol. 2022;196:1170-1174.
    PubMed    


    February 2022
  73. FOLLOWS GA, Barrington SF, Bhuller KS, Culligan DJ, et al
    Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
    Br J Haematol. 2022 Feb 22. doi: 10.1111/bjh.18083.
    PubMed     Abstract available


  74. ROY I, Smilnak G, Burkart M, Hamilton E, et al
    Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2022 Feb 9. doi: 10.1111/bjh.18054.
    PubMed     Abstract available


  75. SAVANI M, Ahn KW, Chen Y, Ahmed S, et al
    Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
    Br J Haematol. 2022 Feb 2. doi: 10.1111/bjh.18052.
    PubMed     Abstract available


  76. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available


    January 2022
  77. AVIVI I, Luttwak E, Saiag E, Halperin T, et al
    BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Br J Haematol. 2022 Jan 25. doi: 10.1111/bjh.18029.
    PubMed     Abstract available


  78. EL-GALALY TC, Villa D, Cheah CY, Gormsen LC, et al
    Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
    Br J Haematol. 2022 Jan 17. doi: 10.1111/bjh.18016.
    PubMed     Abstract available


  79. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    PubMed    


  80. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    PubMed    


  81. EL-MALLAWANY NK, Curry CV, Allen CE
    Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    Br J Haematol. 2022;196:31-44.
    PubMed     Abstract available


    December 2021
  82. HAEBE S, Keay W, Alig S, Mohr AW, et al
    The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.
    Br J Haematol. 2021 Dec 29. doi: 10.1111/bjh.17990.
    PubMed     Abstract available


  83. REN YM, Shang CY, Liang JH, Yin H, et al
    Prognostic significance of serum immunoglobulin paraprotein in mucosa-associated lymphoid tissue (MALT) lymphoma.
    Br J Haematol. 2021 Dec 28. doi: 10.1111/bjh.18000.
    PubMed     Abstract available


  84. BRANDEFORS L, Sander B, Lundqvist K, Kimby E, et al
    Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
    Br J Haematol. 2021 Dec 27. doi: 10.1111/bjh.18002.
    PubMed     Abstract available


  85. CHIAPPELLA A, Diop F, Agostinelli C, Novo M, et al
    Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
    Br J Haematol. 2021 Dec 23. doi: 10.1111/bjh.17971.
    PubMed     Abstract available


  86. KREISSL S, Voltin CA, Kaul H, Buhnen I, et al
    Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2021 Dec 20. doi: 10.1111/bjh.17997.
    PubMed    


  87. MOLETI ML, Testi AM, Foa R
    Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
    Br J Haematol. 2021 Dec 6. doi: 10.1111/bjh.17979.
    PubMed     Abstract available


    November 2021
  88. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    PubMed    


  89. ZHU Y, Tian S, Xu L, Ma Y, et al
    GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study.
    Br J Haematol. 2021 Nov 21. doi: 10.1111/bjh.17960.
    PubMed     Abstract available


  90. GILLESSEN S, Huttmann A, Vucinic V, Muller H, et al
    Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Gro
    Br J Haematol. 2021 Nov 14. doi: 10.1111/bjh.17878.
    PubMed     Abstract available


  91. GUTIERREZ-GARCIA G, Martinez C, Boumendil A, Finel H, et al
    Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17939.
    PubMed     Abstract available


  92. BANERJEE R, Midha S, Kelkar AH, Goodman A, et al
    Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17945.
    PubMed    


  93. URBAN R, Chow R, Pickles T, Chan M, et al
    The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma.
    Br J Haematol. 2021 Nov 4. doi: 10.1111/bjh.17684.
    PubMed    


  94. LEONCINI L
    Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.
    Br J Haematol. 2021 Nov 2. doi: 10.1111/bjh.17922.
    PubMed    


  95. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available


  96. KAJI D, Kusakabe M, Sakata-Yanagimoto M, Makishima K, et al
    Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
    Br J Haematol. 2021;195:585-594.
    PubMed     Abstract available


  97. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    PubMed    


    October 2021
  98. ZHANG S, Zhang T, Liu H, Zhao J, et al
    Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Br J Haematol. 2021 Oct 19. doi: 10.1111/bjh.17894.
    PubMed     Abstract available


  99. HALLIGAN SJ, Grainge MJ, Martinez-Calle N, Fox CP, et al
    Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
    Br J Haematol. 2021 Oct 18. doi: 10.1111/bjh.17896.
    PubMed     Abstract available


  100. BROCKELMANN PJ
    Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?
    Br J Haematol. 2021 Oct 14. doi: 10.1111/bjh.17891.
    PubMed    


  101. MOORE DC, Soni AC, Hu B, Smith ET, et al
    Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Br J Haematol. 2021 Oct 12. doi: 10.1111/bjh.17886.
    PubMed    


  102. DLOUHY I, Karube K, Enjuanes A, Salaverria I, et al
    Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17858.
    PubMed     Abstract available


  103. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available


  104. ZHANG YC, Wang JN, Ma SY, Cai J, et al
    Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 7. doi: 10.1111/bjh.17849.
    PubMed     Abstract available


  105. RICHTER J, John K, Staiger AM, Rosenwald A, et al
    Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
    Br J Haematol. 2021 Oct 6. doi: 10.1111/bjh.17874.
    PubMed     Abstract available


  106. AMAADOR K, Kersten MJ, Visser O, Brink M, et al
    Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2021 Oct 3. doi: 10.1111/bjh.17856.
    PubMed     Abstract available


  107. GUPTA S, Alexander S, Pole JD, Sutradhar R, et al
    Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 1. doi: 10.1111/bjh.17862.
    PubMed     Abstract available


  108. RUDZKI Z, Starczynski J, Dowds J, Pemberton N, et al
    In situ follicular neoplasia with translocation of BCL6 - a new variant with different immunohistochemical properties.
    Br J Haematol. 2021;195:154.
    PubMed    


  109. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available


    September 2021
  110. TOPP MS, van Meerten T, Houot R, Minnema MC, et al
    Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Sep 29. doi: 10.1111/bjh.17673.
    PubMed     Abstract available


  111. RIEDELL PA, Hamadani M, Ahn KW, Litovich C, et al
    Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
    Br J Haematol. 2021 Sep 28. doi: 10.1111/bjh.17865.
    PubMed     Abstract available


  112. LIU W, Chen X, Fan J, Zhu M, et al
    Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Br J Haematol. 2021 Sep 16. doi: 10.1111/bjh.17729.
    PubMed    


  113. GERHARD-HARTMANN E, Goergen H, Brockelmann PJ, Mottok A, et al
    9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17793.
    PubMed     Abstract available


  114. BASTIDAS-MORA G, Bea S, Navarro A, Gine E, et al
    Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17815.
    PubMed     Abstract available


  115. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    PubMed    


  116. LUTFI F, Holtzman NG, Kansagra AJ, Mustafa Ali M, et al
    The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17738.
    PubMed     Abstract available


  117. BORCHMANN S
    Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17796.
    PubMed    


  118. HODSON DJ
    Diffuse large B-cell lymphoma genetics - simplifying the subtyping.
    Br J Haematol. 2021 Sep 7. doi: 10.1111/bjh.17803.
    PubMed    


  119. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available



  120. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    PubMed    


    August 2021
  121. MORIN RD, Arthur SE, Hodson DJ
    Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17811.
    PubMed     Abstract available


  122. LADDAGA FE, Masciopinto P, Nardelli C, Vacca MP, et al
    In male Hodgkin lymphoma patients, impaired fertility may be improved by non-gonadotoxic therapy.
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17767.
    PubMed     Abstract available


  123. MARTINEZ-CALLE N, Isbell LK, Cwynarski K, Schorb E, et al
    Advances in treatment of elderly primary central nervous system lymphoma.
    Br J Haematol. 2021 Aug 26. doi: 10.1111/bjh.17799.
    PubMed     Abstract available


  124. FJORDEN K, Ekberg S, Kuric N, Smedby KE, et al
    Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
    Br J Haematol. 2021 Aug 25. doi: 10.1111/bjh.17792.
    PubMed    


  125. NOGUCHI K, Ikawa Y, Takenaka M, Sakai Y, et al
    Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Br J Haematol. 2021 Aug 22. doi: 10.1111/bjh.17776.
    PubMed    


  126. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available


  127. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available


  128. EICHENAUER DA, Buhnen I, Kreissl S, Goergen H, et al
    Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17770.
    PubMed     Abstract available


  129. MISHINA T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, et al
    Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
    Br J Haematol. 2021 Aug 10. doi: 10.1111/bjh.17765.
    PubMed     Abstract available


  130. KESAVAN M, Zammar G, McQuillan JT, Macdonald WBG, et al
    Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17758.
    PubMed    


  131. KAJI FA, Martinez-Calle N, Bishton MJ, Figueroa R, et al
    Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17747.
    PubMed     Abstract available


  132. CASTILLO JJ, LaMacchia J, Flynn CA, Sarosiek S, et al
    Plasmablastic lymphoma transformation in a patient with Waldenstrom macroglobulinemia treated with ibrutinib.
    Br J Haematol. 2021 Aug 6. doi: 10.1111/bjh.17759.
    PubMed    


  133. LANDSBURG DJ, Barta SK, Ramchandren R, Batlevi C, et al
    Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
    Br J Haematol. 2021 Aug 2. doi: 10.1111/bjh.17730.
    PubMed     Abstract available


  134. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    PubMed    


  135. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    PubMed    


  136. CORDOBA R, Luminari S, Eyre TA
    The use of frailty assessments in treating older adults with aggressive lymphomas.
    Br J Haematol. 2021;194:677-685.
    PubMed     Abstract available


    July 2021
  137. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available


  138. LYU R, Wang T, Wang Y, Xiong W, et al
    Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17703.
    PubMed     Abstract available


  139. RINALDI F, Marchesi F, Palombi F, Pelosi A, et al
    MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
    Br J Haematol. 2021 Jul 28. doi: 10.1111/bjh.17734.
    PubMed     Abstract available


  140. ALCOCEBA M, Garcia-Alvarez M, Chillon MC, Jimenez C, et al
    Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
    Br J Haematol. 2021 Jul 27. doi: 10.1111/bjh.17719.
    PubMed     Abstract available


  141. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available


  142. OLUWOLE OO, Bouabdallah K, Munoz J, De Guibert S, et al
    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17527.
    PubMed     Abstract available


  143. CHAPMAN JR, Bouska AC, Zhang W, Alderuccio JP, et al
    EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Br J Haematol. 2021 Jul 17. doi: 10.1111/bjh.17708.
    PubMed     Abstract available


  144. OHKI K, Kiyokawa N, Watanabe S, Iwafuchi H, et al
    Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).
    Br J Haematol. 2021 Jul 13. doi: 10.1111/bjh.17639.
    PubMed     Abstract available


  145. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available


  146. HARADA T, Iwasaki H, Muta T, Urata S, et al
    Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Br J Haematol. 2021;194:101-110.
    PubMed     Abstract available


    June 2021
  147. BUSSOT L, Chevalier S, Cristante J, Grange B, et al
    Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
    Br J Haematol. 2021 Jun 21. doi: 10.1111/bjh.17550.
    PubMed     Abstract available


  148. YUE LM, Chau D, Kwong YL, Tse E, et al
    Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
    Br J Haematol. 2021 Jun 13. doi: 10.1111/bjh.17581.
    PubMed    


  149. SIMA A, Hollander P, Baecklund E, Smedby KE, et al
    Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17577.
    PubMed     Abstract available


  150. KOWA JY, Millard T, Goldman A, Sharma RK, et al
    Are treatment response assessment maps (TRAMs) and (18) F-choline positron emission tomography the future of central nervous system lymphoma imaging?
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17632.
    PubMed    


  151. SABATINI PJB, Tremblay-LeMay RMA, Ahmadi Moghaddam P, Delabie JMA, et al
    Marginal zone lymphoma transdifferentiated to histiocytic sarcoma.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17582.
    PubMed    


  152. RUMMEL MJ, Janssens A, MacDonald D, Keating MM, et al
    A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Br J Haematol. 2021;193:1123-1133.
    PubMed     Abstract available


  153. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available


  154. LAKHOTIA R, Roschewski M
    Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Br J Haematol. 2021;193:867-881.
    PubMed     Abstract available


    May 2021
  155. LEE S, Fujita K, Morishita T, Oiwa K, et al
    Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 26. doi: 10.1111/bjh.17554.
    PubMed     Abstract available


  156. GENUARDI E, Romano G, Beccuti M, Alessandria B, et al
    Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Br J Haematol. 2021 May 18. doi: 10.1111/bjh.17519.
    PubMed     Abstract available


  157. SETHI TK, Montanari F, Foss F, Reddy N, et al
    How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sezary syndrome.
    Br J Haematol. 2021 May 14. doi: 10.1111/bjh.17458.
    PubMed     Abstract available


  158. RAMPOTAS A, Wilson MR, Lomas O, Denny N, et al
    Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17513.
    PubMed     Abstract available


  159. HENTRICH M, Muller M, Wyen C, Bogner J, et al
    Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17515.
    PubMed    


  160. ABU SABAA A, Morth C, Hasselblom S, Hedstrom G, et al
    Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.
    Br J Haematol. 2021 May 5. doi: 10.1111/bjh.17206.
    PubMed     Abstract available


  161. WANG C, Althof PA, Bi C, Zhang W, et al
    A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17255.
    PubMed    


  162. BALASUBRAMANIAN S, Wang S, Major C, Hodkinson B, et al
    Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP +/- ibrutinib.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17450.
    PubMed     Abstract available


  163. MA SY, Tian XP, Cai J, Su N, et al
    A prognostic immune risk score for diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17478.
    PubMed     Abstract available


  164. CHIRON D
    Towards ecosystem integration for a better understanding of aggressiveness of B-cell lymphomas.
    Br J Haematol. 2021;193:447-448.
    PubMed    


    April 2021
  165. LAPENA-RODRIGUEZ M, Garces-Albir M, Gadea-Mateo R, Mata-Cano D, et al
    Multiple small bowel perforations during the treatment of primary intestinal extranodal natural killer/T-cell lymphoma, nasal type.
    Br J Haematol. 2021 Apr 29. doi: 10.1111/bjh.17229.
    PubMed    


  166. HABOT-WILNER Z, Frenkel S, Pe'er J
    Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
    Br J Haematol. 2021 Apr 26. doi: 10.1111/bjh.17451.
    PubMed     Abstract available


  167. KHURANA A, Maurer MJ
    Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17433.
    PubMed    


  168. LOH Z, Salvaris R, Chong G, Churilov L, et al
    Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17436.
    PubMed     Abstract available


  169. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available


  170. OVERWEEL AFP, Budel LM, Sandberg Y
    Cutaneous blastoid mantle cell lymphoma.
    Br J Haematol. 2021 Apr 5. doi: 10.1111/bjh.17452.
    PubMed    


  171. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available


  172. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available


  173. POLVERELLI N, Elli EM, Abruzzese E, Palumbo GA, et al
    Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Br J Haematol. 2021;193:356-368.
    PubMed     Abstract available


    March 2021
  174. CONDOM M, Climent F, Fernandez D, Colomer D, et al
    Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience.
    Br J Haematol. 2021;192:1020-1025.
    PubMed     Abstract available


    February 2021
  175. MIKHAEEL NG, Cunningham D, Counsell N, McMillan A, et al
    FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Br J Haematol. 2021;192:504-513.
    PubMed     Abstract available


    January 2021
  176. RODRIGUEZ-PINILLA SM, Domingo-Domenech E, Climent F, Sanchez J, et al
    Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
    Br J Haematol. 2021;192:82-99.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: